Source:Journal of Neuroscience Methods
Author(s): Tomer Illouz, Ravit Madar, Kathleen Griffioen, Eitan Okun
BackgroundAmyloid-β (Aβ), a hallmark of Alzheimer's disease (AD), has long been a focus of basic and translation research in AD. Quantification and dissociation of the Aβ fractions in their soluble and insoluble forms, is a key factor in numerous AD studies.New MethodHere we provide a generalized sandwich-enzyme-linked-immuno-sorbent-assay (sELISA) protocol for quantification of human and murine Aβ1-40 and Aβ1-42 and dissociation of these peptides to their soluble-oligomeric and insoluble-fibrillar forms.ResultsWe have validated the levels of soluble and insoluble Aβ1-40 and Aβ1-42 in the 5XFAD AD and the Ts65Dn Down-Syndrome (DS) mouse models in both the cortex, hippocampus and blood as follows: (1) blood levels of Aβ1-40 and Aβ1-42 are elevated in both mouse strains. (2) 5XFAD mice exhibit elevated soluble and insoluble Aβ1-40 in cortical and hippocampal tissues, soluble Aβ1-42 in the hippocampus, and insoluble Aβ1-42in both cortical and hippocampal tissues (3) Ts65Dn mice exhibit elevated levels of Aβ1-40 in the cortex.Comparison with Existing MethodsSeveral methodologies have been proposed for the high throughput measure of Aβ, including HPLC-mass-spectrometry, micro-immunoelectrodes, immunoprecipitation and ELISA. Although commercial sELISA kits are widely used, herein, we describe a more accessible and cost-effective in-house protocol enabling to measure either human or murine, soluble and insoluble Aβ1-40 and Aβ1-42 levels.ConclusionsWe provide a streamlined and accessible protocol for the assessment of soluble and insoluble Aβ1-40 and Aβ1-42 levels from mouse or human origins, enabling a higher accessibility for researchers in the field to generate reliable Aβ-related measurements.
from # All Medicine by Alexandros G. Sfakianakis via alkiviadis.1961 on Inoreader http://ift.tt/2tRuSGU
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.